Sanofi is signaling it's ready to make bigger acquisitions than it has in the past, a move that investors welcomed with a 5.3% jump in the French drugmaker's shares. The company also raised its 2026 growth targets again, underscoring confidence in its strategy.
CEO Belen Garijo is focused on building Sanofi's next growth engine before Dupixent, its blockbuster asthma drug co-marketed with Regeneron Pharmaceuticals, loses patent protection in the early 2030s. Dupixent is one of the world's best-selling medicines, and its eventual patent expiry represents a major revenue cliff that Sanofi must navigate.
Open to bigger deals
Management says a strategic review, due to add detail before year-end, is meant to speed decisions and sharpen where the company spends its research and dealmaking dollars. The key signal: Sanofi is open to paying up for late-stage medicines—those closer to approval—or products already on the market, even if that means going beyond its typical $2-5 billion deal size, as CFO Francois Roger put it.
Those assets cost more because they're nearer to generating revenue, which matters as Sanofi heads toward a “trial-data wave” expected in 2027 and, later on, the Dupixent patent cliff. By acquiring later-stage drugs, Sanofi can potentially fill revenue gaps more quickly than by relying solely on its own research pipeline.
Sanofi says it will mostly stick to familiar areas like immunology, rare diseases, and vaccines, though it also hinted at selective bets in “white spaces” where medical needs are high. This suggests a disciplined approach, focusing on areas where the company already has expertise.
Financial firepower
With third-quarter profit and sales beating expectations, analysts estimate the company has roughly €20 billion of deal capacity to work with. That's a substantial war chest, but it also puts pressure on management to deploy it wisely.
Bigger, later-stage deals can steady earnings faster, but they also tend to come with higher price tags. In accounting terms, more of the purchase price ends up as goodwill and other intangibles on the balance sheet, which only looks smart if the acquired drug sales show up quickly and reliably.
If they don't, the “premium” can linger as a drag on reported profit through amortization, or in the worst case, a painful write-down. That's why Sanofi's next moves are likely to be judged less by headline deal size and more by whether any acquisition improves near-to-mid-term earnings visibility as the company approaches the 2027 clinical readouts and the early-2030s Dupixent cliff.
What it means for investors
For everyday investors, Sanofi's shift toward larger deals is a double-edged sword. On one hand, it shows management is proactive about addressing the Dupixent patent cliff, which is a known risk. On the other, bigger acquisitions carry more execution risk and can dilute shareholder value if they overpay.
Investors should watch for details from the strategic review, expected before year-end, and any specific acquisition announcements. The company's ability to integrate new assets and deliver on its raised 2026 targets will be key.
Sanofi's move also reflects a broader trend in pharma, where companies are increasingly turning to M&A to bolster pipelines as patent expiries loom. Similar dynamics have been seen in other sectors, such as Glencore's asset sales and Hengrui's licensing deals, where companies are reshaping their portfolios to drive growth.
For now, the market's positive reaction suggests investors are giving Sanofi the benefit of the doubt. But the real test will come when the company puts its money to work.
